CD274 and non-small cell lung carcinoma: Particularly, a longer PFS for anti-PD-1 treatments (HR = 0.71, 95% CI, 0.58–0.88), for anti-PD-L1 ones (HR = 0.64, 95% CI, 0.56–0.74), monotherapy (HR = 0.72, 95% CI, 0.56–0.92), and combination (HR = 0.64, 95% CI, 0.57–0.71) was evidenced in male NSCLC patients.